Total trials
215
Active
37
Phase 3
19
Total enrollment
173,394
Pipeline matrix
Showing 5 of 5 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Grape Seed Extracts | — | — | — | — | — | 1 | |
| ESP block with saline | — | — | — | — | — | 1 | |
| Wound infiltration with saline | — | — | — | — | — | 1 | |
| ESP block with local anesthetic | — | — | — | — | — | 1 | |
| Wound infiltration with local anesthetic | — | — | — | — | — | 1 |
Next readouts
- 2025-12-31
- 2026-05-20
Top conditions
- Anesthesia Brain Monitoring8
- Type 2 Diabetes6
- Cirrhosis4
- Respiratory Failure3
- Inflammation3
- Type 2 Diabetes Mellitus3
- Body Image3
- Morbid Obesity3
Frequently asked questions about University of Padova
- How many clinical trials does University of Padova have on ClinicalTrials.gov?
- University of Padova is listed as the lead sponsor on 215 clinical trials in ClinicalTrials.gov, 37 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Padova's trials are in Phase 3?
- 19 of University of Padova's trials are in Phase 3, spread across 5 active drug programs.
- What therapeutic areas does University of Padova focus on?
- University of Padova's most-studied conditions on ClinicalTrials.gov are Anesthesia Brain Monitoring, Type 2 Diabetes, Cirrhosis, Respiratory Failure, Inflammation.
- When are University of Padova's next clinical trial readouts?
- University of Padova has 2 upcoming primary-completion readouts tracked here; the soonest is “Effect of Procyanidins in Leaky Gut Repairing in IBD”, expected around 2025-12-31.